Tada and colleagues reported recently that the treatment of advanced gastric cancer patients with ramucirumab–a fully humanized IgG monoclonal anti-VEGF receptor 2 (VEGFR2) antibody–not only increased CD8+ T-cell tumor infiltration, but also significantly reduced the frequency of CD45RA− FOXP3high CD4+ cells (effector regulatory T cells [eTreg]) in tumors. Here, CD4 is linked to neoplasm.